Targeted therapies for the treatment of pediatric non-hodgkin lymphomas: Present and future

Pharmaceuticals

Volumn 9, Issue 2, 2016, Pages

  Sorge, Caryn E ^a   McDaniel, Jenny K ^a   Xavier, Ana C ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Non Hodgkin lymphoma; Pediatric; Targeted therapies

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BELINOSTAT; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CD20 ANTIGEN; CD30 ANTIGEN; CRIZOTINIB; HISTONE DEACETYLASE; IBRITUMOMAB TIUXETAN; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NELARABINE; NIVOLUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RITUXIMAB; ROMIDEPSIN; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHILDHOOD DISEASE; CUTANEOUS T CELL LYMPHOMA; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INACTIVATION; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; LYMPHOCYTOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR;

EID: 84973278425     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph9020028     Document Type: Review

References (91)

1. Reff, M.E.; Carner, K.; Chambers, K.S.; Chinn, P.C.; Leonard, J.E.; Raab, R.; Newman, R.A.; Hanna, N.; Anderson, D.R. Depletion of b cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83, 435-445. [PubMed]
2. Maloney, D.G.; Smith, B.; Rose, A. Rituximab: Mechanism of action and resistance. Semin. Oncol. 2002, 29, 2-9. [CrossRef] [PubMed]
3. Coiffier, B.; Haioun, C.; Ketterer, N.; Engert, A.; Tilly, H.; Ma, D.; Johnson, P.; Lister, A.; Feuring-Buske, M.; Radford, J.A., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998, 92, 1927-1932. [PubMed]
4. Czuczman, M.S.; Grillo-Lopez, A.J.; White, C.A.; Saleh, M.; Gordon, L.; LoBuglio, A.F.; Jonas, C.; Klippenstein, D.; Dallaire, B.; Varns, C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and chop chemotherapy. J. Clin. Oncol. 1999, 17, 268-276. [PubMed]
5. Vose, J.M.; Link, B.K.; Grossbard, M.L.; Czuczman, M.; Grillo-Lopez, A.; Gilman, P.; Lowe, A.; Kunkel, L.A.; Fisher, R.I. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-hodgkin’s lymphoma. J. Clin. Oncol. 2001, 19, 389-397. [CrossRef] [PubMed]
6. Wilson, W.H.; Gutierrez, M.; O’Connor, P.; Frankel, S.; Jaffe, E.; Chabner, B.A.; Grossbard, M.L. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted epoch-r. Semin. Oncol. 2002, 29, 41-47. [CrossRef] [PubMed]
7. Thomas, D.A.; Faderl, S.; O’Brien, S.; Bueso-Ramos, C.; Cortes, J.; Garcia-Manero, G.; Giles, F.J.; Verstovsek, S.; Wierda, W.G.; Pierce, S.A., et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult burkitt and burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106, 1569-1580. [CrossRef] [PubMed]
8. Pfreundschuh, M.; Trumper, L.; Osterborg, A.; Pettengell, R.; Trneny, M.; Imrie, K.; Ma, D.; Gill, D.; Walewski, J.; Zinzani, P.L., et al. Chop-like chemotherapy plus rituximab versus chop-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the mabthera international trial (mint) group. Lancet Oncol. 2006, 7, 379-391. [CrossRef]
9. Glass, B.; Kloess, M.; Bentz, M.; Schlimok, G.; Berdel, W.E.; Feller, A.; Trumper, L.; Loeffler, M.; Pfreundschuh, M.; Schmitz, N., et al. Dose-escalated chop plus etoposide (megachoep) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006, 107, 3058-3064. [CrossRef] [PubMed]
10. Perkins, S.L.; Lones, M.A.; Davenport, V.; Cairo, M.S. B-cell non-Hodgkin’s lymphoma in children and adolescents: Surface antigen expression and clinical implications for future targeted bioimmune therapy: A children’s cancer group report. Clin. Adv. Hematol. Oncol. 2003, 1, 314-317. [PubMed]
11. Nozu, K.; Iijima, K.; Fujisawa, M.; Nakagawa, A.; Yoshikawa, N.; Matsuo, M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr. Nephrol. 2005, 20, 1660-1663. [CrossRef] [PubMed]
12. Skoda-Smith, S.; Douglas, V.K.; Mehta, P.; Graham-Pole, J.; Wingard, J.R. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and rituximab. Bone Marrow Transp. 2001, 27, 329-332. [CrossRef] [PubMed]
13. Attias, D.; Weitzman, S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: A review of available evidence. Curr. Opin. Pediatr. 2008, 20, 17-22. [CrossRef] [PubMed]
14. Attarbaschi, A.; Dworzak, M.; Steiner, M.; Urban, C.; Fink, F.M.; Reiter, A.; Gadner, H.; Mann, G. Outcome of children with primary resistant or relapsed non-hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the austrian cooperative study group. Pediatr. Blood Cancer 2005, 44, 70-76. [CrossRef] [PubMed]
15. Kobrinsky, N.L.; Sposto, R.; Shah, N.R.; Anderson, J.R.; DeLaat, C.; Morse, M.; Warkentin, P.; Gilchrist, G.S.; Cohen, M.D.; Shina, D., et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: Children’s cancer group study ccg-5912. J. Clin. Oncol. 2001, 19, 2390-2396. [PubMed]
16. Philip, T.; Hartmann, O.; Pinkerton, R.; Zucker, J.M.; Gentet, J.C.; Lamagnere, J.P.; Berhendt, H.; Perel, Y.; Otten, J.; Lutz, P., et al. Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: A report from the societe francaise d’oncologie pediatrique. Blood 1993, 81, 2003-2006. [PubMed]
17. Griffin, T.C.; Weitzman, S.; Weinstein, H.; Chang, M.; Cairo, M.; Hutchison, R.; Shiramizu, B.; Wiley, J.; Woods, D.; Barnich, M., et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the children’s oncology group. Pediatr. Blood Cancer 2009, 52, 177-181. [CrossRef] [PubMed]
18. Meinhardt, A.; Burkhardt, B.; Zimmermann, M.; Borkhardt, A.; Kontny, U.; Klingebiel, T.; Berthold, F.; Janka-Schaub, G.; Klein, C.; Kabickova, E., et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and burkitt leukemia. J. Clin. Oncol. 2010, 28, 3115-3121. [CrossRef] [PubMed]
19. Goldman, S.; Smith, L.; Anderson, J.R.; Perkins, S.; Harrison, L.; Geyer, M.B.; Gross, T.G.; Weinstein, H.; Bergeron, S.; Shiramizu, B., et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: A children’s oncology group report. Leukemia 2013, 27, 1174-1177. [CrossRef] [PubMed]
20. Patte, C.; Auperin, A.; Gerrard, M.; Michon, J.; Pinkerton, R.; Sposto, R.; Weston, C.; Raphael, M.; Perkins, S.L.; McCarthy, K., et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007, 109, 2773-2780. [PubMed]
21. Cairo, M.S.; Sposto, R.; Gerrard, M.; Auperin, A.; Goldman, S.C.; Harrison, L.; Pinkerton, R.; Raphael, M.; McCarthy, K.; Perkins, S.L., et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: Results of the FAB LMB 96 study. J. Clin. Oncol. 2012, 30, 387-393. [PubMed]
22. Goldman, S.; Smith, L.; Galardy, P.; Perkins, S.L.; Frazer, J.K.; Sanger, W.; Anderson, J.R.; Gross, T.G.; Weinstein, H.; Harrison, L., et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive burkitt lymphoma/leukaemia: A children’s oncology group report. Br. J. Haematol. 2014, 167, 394-401. [CrossRef] [PubMed]
23. Cheson, B.D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003, 101, 391-398. [CrossRef] [PubMed]
24. Witzig, T.E.; Gordon, L.I.; Cabanillas, F.; Czuczman, M.S.; Emmanouilides, C.; Joyce, R.; Pohlman, B.L.; Bartlett, N.L.; Wiseman, G.A.; Padre, N., et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 2002, 20, 2453-2463. [CrossRef] [PubMed]
25. Witzig, T.E.; Flinn, I.W.; Gordon, L.I.; Emmanouilides, C.; Czuczman, M.S.; Saleh, M.N.; Cripe, L.; Wiseman, G.; Olejnik, T.; Multani, P.S., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J. Clin. Oncol. 2002, 20, 3262-3269. [CrossRef] [PubMed]
26. Cooney-Qualter, E.; Krailo, M.; Angiolillo, A.; Fawwaz, R.A.; Wiseman, G.; Harrison, L.; Kohl, V.; Adamson, P.C.; Ayello, J.; vande Ven C.; et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-hodgkin’s lymphoma: A children’s oncology group study. Clin. Cancer Res. 2007, 13, 5652s-5660s. [CrossRef] [PubMed]
27. Lau, S.K.; Weiss, L.M.; Chu, P.G. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: A comparative immunohistochemical study with kit (CD117) and CD30. Mod. Pathol. 2007, 20, 320-325. [CrossRef] [PubMed]
28. Gorczyca, W.; Tsang, P.; Liu, Z.; Wu, C.D.; Dong, H.Y.; Goldstein, M.; Cohen, P.; Gangi, M.; Weisberger, J. CD30-positive T-cell lymphomas co-expressing CD15: An immunohistochemical analysis. Int. J. Oncol. 2003, 22, 319-324. [CrossRef] [PubMed]
29. Hamblett, K.J.; Senter, P.D.; Chace, D.F.; Sun, M.M.; Lenox, J.; Cerveny, C.G.; Kissler, K.M.; Bernhardt, S.X.; Kopcha, A.K.; Zabinski, R.F., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 2004, 10, 7063-7070. [CrossRef] [PubMed]
30. Doronina, S.O.; Mendelsohn, B.A.; Bovee, T.D.; Cerveny, C.G.; Alley, S.C.; Meyer, D.L.; Oflazoglu, E.; Toki, B.E.; Sanderson, R.J.; Zabinski, R.F., et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 2006, 17, 114-124. [CrossRef] [PubMed]
31. Younes, A.; Bartlett, N.L.; Leonard, J.P.; Kennedy, D.A.; Lynch, C.M.; Sievers, E.L.; Forero-Torres, A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 2010, 363, 1812-1821. [CrossRef] [PubMed]
32. Younes, A.; Gopal, A.K.; Smith, S.E.; Ansell, S.M.; Rosenblatt, J.D.; Savage, K.J.; Ramchandren, R.; Bartlett, N.L.; Cheson, B.D.; de Vos S.; et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 2012, 30, 2183-2189. [CrossRef] [PubMed]
33. Younes, A.; Connors, J.M.; Park, S.I.; Fanale, M.; O’Meara, M.M.; Hunder, N.N.; Huebner, D.; Ansell, S.M. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol. 2013, 14, 1348-1356. [CrossRef]
34. Mikles, B.; Levine, J.; Gindin, T.; Bhagat, G.; Satwani, P. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma. J. Pediatr. Hematol. Oncol. 2014, 36, e85-e87. [CrossRef] [PubMed]
35. Neville, K.; Gore, L.; Mauz-Korholz, C.; Rosole, A.; Landman-Parker, J.; Sanches de Toledo, J.; Beishizen, A.; Franklin, A.R.K.; Fasanmade, A.; Wang, J.G., et al. Phase I/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: Interim phase I safety data. J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol. 2013, 31, 10028.
36. Locatelli, F.; Neville, K.; Rosolen, A.; Landman-Parker, J.; Aladjidi, N.; Beishuizen, A.; Daw, S.; Gore, L.; Franklin, A.R.K.; Fasanmade, A., et al. Phase I/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: Preliminary phase 2 data for brentuximab vedotin 1.8 mg/kg in the hl study arm. Blood 2013, 122, 4378.
37. Kisor, D.F.; Plunkett, W.; Kurtzberg, J.; Mitchell, B.; Hodge, J.P.; Ernst, T.; Keating, M.J.; Gandhi, V. Pharmacokinetics of nelarabine and 9-β-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol. 2000, 18, 995-1003. [PubMed]
38. Cooper, T.M. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther. Clin. Risk Manag. 2007, 3, 1135-1141. [PubMed]
39. Rodriguez, C.O., Jr.; Stellrecht, C.M.; Gandhi, V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003, 102, 1842-1848. [CrossRef] [PubMed]
40. Kurtzberg, J.; Ernst, T.J.; Keating, M.J.; Gandhi, V.; Hodge, J.P.; Kisor, D.F.; Lager, J.J.; Stephens, C.; Levin, J.; Krenitsky, T., et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 2005, 23, 3396-3403. [CrossRef] [PubMed]
41. Berg, S.L.; Blaney, S.M.; Devidas, M.; Lampkin, T.A.; Murgo, A.; Bernstein, M.; Billett, A.; Kurtzberg, J.; Reaman, G.; Gaynon, P., et al. Phase II study of nelarabine (compound 506u78) in children and young adults with refractory T-cell malignancies: A report from the children’s oncology group. J. Clin. Oncol. 2005, 23, 3376-3382. [CrossRef] [PubMed]
42. Cohen, M.H.; Johnson, J.R.; Massie, T.; Sridhara, R.; McGuinn, W.D., Jr.; Abraham, S.; Booth, B.P.; Goheer, M.A.; Morse, D.; Chen, X.H., et al. Approval summary: Nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin. Cancer Res. 2006, 12, 5329-5335. [CrossRef] [PubMed]
43. Commander, L.A.; Seif, A.E.; Insogna, I.G.; Rheingold, S.R. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br. J. Haematol. 2010, 150, 345-351. [CrossRef] [PubMed]
44. Dunsmore, K.P.; Devidas, M.; Linda, S.B.; Borowitz, M.J.; Winick, N.; Hunger, S.P.; Carroll, W.L.; Camitta, B.M. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: A report from the children’s oncology group. J. Clin. Oncol. 2012, 30, 2753-2759. [CrossRef] [PubMed]
45. Winter, S.S.; Dunsmore, K.P.; Devidas, M.; Eisenberg, N.; Asselin, B.L.; Wood, B.L.; Leonard Rn, M.S.; Murphy, J.; Gastier-Foster, J.M.; Carroll, A.J., et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s oncology group study aall0434. Pediatr. Blood Cancer 2015, 62, 1176-1183. [CrossRef] [PubMed]
46. Burkhardt, B.; Reiter, A.; Landmann, E.; Lang, P.; Lassay, L.; Dickerhoff, R.; Lakomek, M.; Henze, G.; von Stackelberg A. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the berlin-frankfurt-muenster group. J. Clin. Oncol. 2009, 27, 3363-3369. [CrossRef] [PubMed]
47. Houghton, P.J.; Morton, C.L.; Kolb, E.A.; Lock, R.; Carol, H.; Reynolds, C.P.; Keshelava, N.; Maris, J.M.; Keir, S.T.; Wu, J., et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50, 37-45. [CrossRef] [PubMed]
48. Chauhan, D.; Li, G.; Auclair, D.; Hideshima, T.; Podar, K.; Mitsiades, N.; Mitsiades, C.; Chen, L.B.; Munshi, N.; Saxena, S., et al. 2-methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating heat shock protein-27. Apoptosis 2004, 9, 149-155. [CrossRef] [PubMed]
49. Mitsiades, N.; Mitsiades, C.S.; Richardson, P.G.; Poulaki, V.; Tai, Y.T.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M., et al. The proteasome inhibitor ps-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003, 101, 2377-2380. [CrossRef] [PubMed]
50. Ma, M.H.; Yang, H.H.; Parker, K.; Manyak, S.; Friedman, J.M.; Altamirano, C.; Wu, Z.Q.; Borad, M.J.; Frantzen, M.; Roussos, E., et al. The proteasome inhibitor ps-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 2003, 9, 1136-1144. [PubMed]
51. Messinger, Y.; Gaynon, P.; Raetz, E.; Hutchinson, R.; Dubois, S.; Glade-Bender, J.; Sposto, R.; van der Giessen, J.; Eckroth, E.; Bostrom, B.C. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (all): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr. Blood Cancer 2010, 55, 254-259. [CrossRef] [PubMed]
52. Messinger, Y.H.; Gaynon, P.S.; Sposto, R.; van der Giessen J.; Eckroth, E.; Malvar, J.; Bostrom, B.C.; Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic advances in childhood leukemia & lymphoma (TACL) study. Blood 2012, 120, 285-290. [PubMed]
53. Peart, M.J.; Tainton, K.M.; Ruefli, A.A.; Dear, A.E.; Sedelies, K.A.; O’Reilly, L.A.; Waterhouse, N.J.; Trapani, J.A.; Johnstone, R.W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003, 63, 4460-4471. [PubMed]
54. Sakajiri, S.; Kumagai, T.; Kawamata, N.; Saitoh, T.; Said, J.W.; Koeffler, H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. 2005, 33, 53-61. [CrossRef] [PubMed]
55. Dokmanovic, M.; Marks, P.A. Prospects: Histone deacetylase inhibitors. J. Cell. Biochem. 2005, 96, 293-304. [CrossRef] [PubMed]
56. Kelly, W.K.; Richon, V.M.; O’Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E., et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9, 3578-3588. [PubMed]
57. Kelly, W.K.; Marks, P.A. Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2005, 2, 150-157. [CrossRef] [PubMed]
58. Kelly, W.K.; O’Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923-3931. [CrossRef] [PubMed]
59. Olsen, E.O.; Kim, Y.; Kuzel, T.; Pacheco, T.; Foss, F.; Parker, S.; Wang, J.G.; Frankel, S.R.; Lis, J.; Duvic, M. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIB trial. J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol. 2006, 24, 7500.
60. Kewitz, S.; Bernig, T.; Staege, M.S. Histone deacetylase inhibition restores cisplatin sensitivity of hodgkin’s lymphoma cells. Leuk. Res. 2012, 36, 773-778. [CrossRef] [PubMed]
61. Bachmann, P.S.; Piazza, R.G.; Janes, M.E.; Wong, N.C.; Davies, C.; Mogavero, A.; Bhadri, V.A.; Szymanska, B.; Geninson, G.; Magistroni, V., et al. Epigenetic silencing of bim in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010, 116, 3013-3022. [CrossRef] [PubMed]
62. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769-784. [CrossRef] [PubMed]
63. Valdez, B.C.; Brammer, J.E.; Li, Y.; Murray, D.; Liu, Y.; Hosing, C.; Nieto, Y.; Champlin, R.E.; Andersson, B.S. Romidepsin targets multiple survival signaling pathways in malignant t cells. Blood Cancer J. 2015, 5, e357. [CrossRef] [PubMed]
64. Panicker, J.; Li, Z.; McMahon, C.; Sizer, C.; Steadman, K.; Piekarz, R.; Bates, S.E.; Thiele, C.J. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. Cell Cycle 2010, 9, 1830-1838. [CrossRef] [PubMed]
65. Perkins, S.L.; Pickering, D.; Lowe, E.J.; Zwick, D.; Abromowitch, M.; Davenport, G.; Cairo, M.S.; Sanger, W.G. Childhood anaplastic large cell lymphoma has a high incidence of alk gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: A genetic and pathological correlation. Br. J. Haematol. 2005, 131, 624-627. [CrossRef] [PubMed]
66. Satwani, P.; Bavishi, S.; Saha, A.; Zhao, F.; Ayello, J.; van de Ven, C.; Chu, Y.; Cairo, M.S. Upregulation of nkg2d ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy 2014, 16, 1431-1440. [CrossRef] [PubMed]
67. Piekarz, R.L.; Robey, R.; Sandor, V.; Bakke, S.; Wilson, W.H.; Dahmoush, L.; Kingma, D.M.; Turner, M.L.; Altemus, R.; Bates, S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous t-cell lymphoma: A case report. Blood 2001, 98, 2865-2868. [CrossRef] [PubMed]
68. Coiffier, B.; Pro, B.; Prince, H.M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Morschhauser, F.; Wilhelm, M.; Pinter-Brown, L., et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses. J. Hematol. Oncol. 2014, 7, 11. [CrossRef] [PubMed]
69. Coiffier, B.; Pro, B.; Prince, H.M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Borchmann, P.; Morschhauser, F.; Wilhelm, M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral t-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 2012, 30, 631-636. [CrossRef] [PubMed]
70. Children’s Oncology Group; Fouladi, M.; Furman, W.L.; Chin, T.; Freeman, B.B., Dudkin, L.; Stewart, C.F.; Krailo, M.D.; Speights, R.; Ingle, A.M., et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A children’s oncology group report. J. Clin. Oncol. 2006, 24, 3678-3685.
71. Lee, H.Z.; Kwitkowski, V.E.; Del Valle, P.L.; Ricci, M.S.; Saber, H.; Habtemariam, B.A.; Bullock, J.; Bloomquist, E.; Li Shen, Y.; Chen, X.H., et al. FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin. Cancer Res. 2015, 21, 2666-2670. [CrossRef] [PubMed]
72. O’Connor, O.A.; Horwitz, S.; Masszi, T.; Van Hoof, A.; Brown, P.; Doorduijn, J.; Hess, G.; Jurczak, W.; Knoblauch, P.; Chawla, S., et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II belief (CLN-19) study. J. Clin. Oncol. 2015, 33, 2492-2499. [CrossRef] [PubMed]
73. Puvvada, S.D.; Li, H.; Rimsza, L.M.; Bernstein, S.H.; Fisher, R.I.; LeBlanc, M.; Schmelz, M.; Glinsmann-Gibson, B.; Miller, T.P.; Maddox, A.M., et al. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: Swog s0520. Leuk. Lymphoma 2016, 1-11. [CrossRef] [PubMed]
74. Choi, Y.L.; Takeuchi, K.; Soda, M.; Inamura, K.; Togashi, Y.; Hatano, S.; Enomoto, M.; Hamada, T.; Haruta, H.; Watanabe, H., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008, 68, 4971-4976. [CrossRef] [PubMed]
75. Griffin, C.A.; Hawkins, A.L.; Dvorak, C.; Henkle, C.; Ellingham, T.; Perlman, E.J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999, 59, 2776-2780. [PubMed]
76. Chen, Y.; Takita, J.; Choi, Y.L.; Kato, M.; Ohira, M.; Sanada, M.; Wang, L.; Soda, M.; Kikuchi, A.; Igarashi, T., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455, 971-974. [CrossRef] [PubMed]
77. Maxson, J.E.; Davare, M.A.; Luty, S.B.; Eide, C.A.; Chang, B.H.; Loriaux, M.M.; Tognon, C.E.; Bottomly, D.; Wilmot, B.; McWeeney, S.K., et al. Therapeutically targetable ALK mutations in leukemia. Cancer Res. 2015, 75, 2146-2150. [CrossRef] [PubMed]
78. Gambacorti-Passerini, C.; Messa, C.; Pogliani, E.M. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 2011, 364, 775-776. [CrossRef] [PubMed]
79. Mosse, Y.P.; Lim, M.S.; Voss, S.D.; Wilner, K.; Ruffner, K.; Laliberte, J.; Rolland, D.; Balis, F.M.; Maris, J.M.; Weigel, B.J., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A children’s oncology group phase 1 consortium study. Lancet Oncol. 2013, 14, 472-480. [CrossRef]
80. Ceccon, M.; Mologni, L.; Giudici, G.; Piazza, R.; Pirola, A.; Fontana, D.; Gambacorti-Passerini, C. Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. Mol. Cancer Res. 2015, 13, 775-783. [CrossRef] [PubMed]
81. Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D.H.; Miller, R.A., et al. The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and b-cell malignancy. Proc. Natl. Acad. Sci. USA 2010, 107, 13075-13080. [CrossRef] [PubMed]
82. Lee, S.; Yin, C.; Ayello, J.; Morris, E.; O’Connell, M.S.; Harrison, L.; van de Ven, C.; Barth, M.; Miles, R.R.; Galardy, P., et al. Ibrutinib significantly prolonged survival in a human burkitt lymphoma (BL) xenograft nsg mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL. Blood 2015, 126, 5117.
83. Lee, S.; Yin, C.; Ayello, J.; Morris, E.; Harrison, L.; van de Ven, C.; Barth, M.; Miles, R.R.; Galardy, P.; Goldman, S., et al. Ibrutinib alone and in combination with dexamethasone and carfilzomib signifiantly inhibits cell proliferation in primary mediastinal B-cell lymphoma (PMBL): Ibrutinib may be a future targeted agent in combination therapy in patients with PMBL. Blood 2015, 126, 4852.
84. Bartlett, N.; LaPlant, B.; Qi, J.; Ansell, S.; Kuruvilla, J.; Reeder, C.; Thye, L.; Anderson, D.; Erlichman, C.; Siegel, B. Ibrutinib monotherapy in relapsed/refractory follicular lymphoma (FL): Preliminary results of a phase 2 consortium (P2C) trial. In Proceedings of the 56th ASH Annual Meeting and Exposition, San Francisco, CA, USA, 9 December 2014; p. 800.
85. Fowler, N.; Nastoupil, L.; de Vos, S.; Knapp, M.; Flinn, I.; Chen, R.; Advani, R.; Bhatia, S.; Martin, P.; Mena, R., et al. Ibrutinib plus rituximab in treatment-naïve patients with follicular lymphoma: Results from a multicenter, phase 2 study. In Proceedings of the 57th ASH Annual Meeting and Exposition, Orlando, FL, USA, 7 December 2015; p. 470.
86. Lannutti, B.J.; Meadows, S.A.; Herman, S.E.; Kashishian, A.; Steiner, B.; Johnson, A.J.; Byrd, J.C.; Tyner, J.W.; Loriaux, M.M.; Deininger, M., et al. Cal-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of b-cell malignancies, inhibits pi3k signaling and cellular viability. Blood 2011, 117, 591-594. [CrossRef] [PubMed]
87. Traynor, K. Idelalisib approved for three blood cancers. Am. J. Health Syst. Pharm. 2014, 71, 1430. [CrossRef] [PubMed]
88. Weber, J. Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 2010, 37, 430-439. [CrossRef] [PubMed]
89. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366, 2455-2465. [CrossRef] [PubMed]
90. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443-2454. [CrossRef] [PubMed]
91. Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 2015, 372, 311-319. [CrossRef] [PubMed]